ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
澳股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
BCAL DIAGNOSTICS LTD
0.052
0.000
成交量:
- -
成交额:
- -
市值:
1,913.95万
市盈率:
-2.61
高:
0.052
开:
0.052
低:
0.052
收:
0.052
52周最高:
0.155
52周最低:
0.052
股本:
3.68亿
流通股本:
2.02亿
量比:
- -
换手率:
- -
股息:
- -
股息率:
- -
每股收益(TTM):
-0.020
每股收益(LYR):
-0.020
净资产收益率:
-121.67%
总资产收益率:
-46.59%
市净率:
7.66
市盈率(LYR):
-2.58
数据加载中...
总览
公司
新闻资讯
公告
BCAL Diagnostics将收购Genetic Signatures股份
投资观察
·
07/07
BCAL诊断公司与Sonic Healthcare USA或就验证后的Breastestplus V2版本商谈商业许可
美股速递
·
05/28
BCAL Diagnostics Ltd 提交Avantect胰腺癌早期检测血液测试的MSAC申请
美股速递
·
03/31
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/BDX.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BDX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","market":"AU","secType":"STK","nameCN":"BCAL DIAGNOSTICS LTD","latestPrice":0.052,"timestamp":1787638320000,"preClose":0.052,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"BCAL DIAGNOSTICS LTD","floatShares":202437334,"shares":368067640,"eps":-0.01993,"marketStatus":"未开盘","change":0,"latestTime":"08-25 16:12:00 AEST","open":0.052,"high":0.052,"low":0.052,"amount":0,"amplitude":0,"askPrice":0.06,"askSize":6450,"bidPrice":0.052,"bidSize":56749,"shortable":3,"etf":0,"ttmEps":-0.01993,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.052,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BDX.AU","preClose":0.065,"auctionPrice":0.063,"auctionVolume":3076,"auction":3,"marketStatus":"盘后竞价","timestamp":1786341616106}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","floatShares":202437334,"roa":"-46.59%","roe":"-121.67%","lyrEps":-0.020136,"shares":368067640,"dividePrice":0,"high":0.052,"amplitude":0,"preClose":0.052,"low":0.052,"week52Low":0.052,"pbRate":"7.66","psRate":"7.54","week52High":0.155,"institutionHeld":0,"latestPrice":0.052,"committee":0.795883,"eps":-0.01993,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.01993,"open":0.052,"prevYearClose":0.105,"prevWeekClose":0.058,"prevMonthClose":0.067,"prevQuarterClose":0.075,"fiveDayClose":0.054,"twentyDayClose":0.071,"sixtyDayClose":0.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BDX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BDX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BDX.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1182337442","title":"BCAL Diagnostics将收购Genetic Signatures股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1182337442","media":"投资观察","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182337442?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 16:48","pubTimestamp":1783414100,"startTime":"0","endTime":"0","summary":"7月2日——BCAL Diagnostics有限公司宣布,将收购GENETIC SIGNATURES有限公司的股份。具体而言,BCAL将以139万澳元的价格,收购GENETIC SIGNATURES公司10.2%的股权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7048","BK7501","GSS.AU","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101703832","title":"BCAL诊断公司与Sonic Healthcare USA或就验证后的Breastestplus V2版本商谈商业许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1101703832","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101703832?lang=zh_cn&edition=fundamental","pubTime":"2026-05-28 06:26","pubTimestamp":1779920771,"startTime":"0","endTime":"0","summary":"BCAL诊断公司与Sonic Healthcare USA可能在验证完成后,就第二代Breastestplus产品展开商业许可协议的谈判。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193985776","title":"BCAL Diagnostics Ltd 提交Avantect胰腺癌早期检测血液测试的MSAC申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1193985776","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193985776?lang=zh_cn&edition=fundamental","pubTime":"2026-03-31 06:12","pubTimestamp":1774908740,"startTime":"0","endTime":"0","summary":"BCAL Diagnostics Ltd 已正式向澳大利亚医疗服务咨询委员会(MSAC)提交了关于其Avantect胰腺癌早期检测血液测试的申请。这一关键步骤标志着该公司在推进该创新诊断工具获得官方批准和潜在报销资格方面取得了重要进展。\nAvantect测试旨在通过简单的血液样本实现胰腺癌的早期发现,有望显著改善这种致命疾病的诊断时间线和患者预后。此次MSAC申请的提交是BCAL Diagnostics Ltd商业化战略中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}]}}